Hospira recalls several injectables over sterility concerns

Hospira issued a voluntary nationwide recall Thursday of four types of injectable solutions after discovering a potential problem with their sterility.

The affected products include:

  • Forty-two lots of 8.4 percent sodium bicarbonate injection 50 mL vials
  • Five lots of NeutTM 5 mL vials
  • Five lots of QuelicinTM 10 mL vials
  • Seven lots of potassium phosphates injection 45 mM vials

The recall comes after a routine simulation of the manufacturing process uncovered the potential for microbial growth, meaning microorganisms may be in the products. However, microorganisms have not been detected in actual batches of the solutions, and no adverse events have been reported to Hospira.

Organizations with any of the affected products should stop use and quarantine them immediately, according to the recall notice.

See the full recall notice, posted by the Food and Drug Administration, here.

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Featured Webinars

Featured Whitepapers